Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC003987 | Panoply™ Human CYP51A1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC003987 | Panoply™ Human CYP51A1 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04545Z | Human CYP51A1 adenoviral particles | Inquiry |
| LV10239L | human CYP51A1 (NM_000786) lentivirus particles | Inquiry |
| LV10240L | human CYP51A1 (NM_001146152) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHG217841 | shRNA set against Rat Cyp51(NM_012941.2) | Inquiry |
| SHG217927 | shRNA set against Human CYP51A1(NM_000786.3) | Inquiry |
| SHG217945 | shRNA set against Mouse Cyp51(NM_020010.2) | Inquiry |
| SHH273769 | shRNA set against Human Cyp51 (NM_000786.3) | Inquiry |
| SHH273773 | shRNA set against Mouse Cyp51 (NM_020010.2) | Inquiry |
| SHH273777 | shRNA set against Rat Cyp51 (NM_012941.2) | Inquiry |
| SHW002447 | shRNA set against Chicken CYP51A1 (NM_001048077) | Inquiry |
| SHW006111 | shRNA set against Danio rerio CYP51 (NM_001001730) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFH004701 | Human CYP51A1 cDNA Clone(NM_001146152.1) | Inquiry |
| CDFR010639 | Rat Cyp51 cDNA Clone(NM_012941.2) | Inquiry |
| MiUTR1H-02644 | CYP51A1 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-03559 | CYP51 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-01360 | CYP51 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-04274 | CYP51A1 miRNA 3'UTR clone | Inquiry |
| CDCB163922 | Chicken CYP51A1 ORF Clone (NM_001048077) | Inquiry |
| CDCB167586 | Danio rerio CYP51 ORF Clone (NM_001001730) | Inquiry |
| CDCR052888 | Mouse Cyp51 ORF clone (NM_020010.2) | Inquiry |
| CDCR052892 | Human CYP51A1 ORF clone (NM_001146152.1) | Inquiry |
| CDCR377796 | Rat Cyp51 ORF Clone(NM_012941.2) | Inquiry |
| CDCS405901 | Human CYP51A1 ORF Clone (BC032322) | Inquiry |